Limited Coverage Drugs - Adefovir

The Ministry of Health has completed a review of tenofovir, entecavir and adefovir for the treatment of chronic hepatitis B.  Based on the results of this review, PharmaCare is changing coverage of and criteria for drugs used in the treatment of chronic Hepatitis B.

PharmaCare is discontinuing coverage of adefovir (Hepsera® and Apo-adefovir) 10 mg tablet.

  • Effective November 27, 2018, no new Special Authority (SA) requests for adefovir will be approved.

  • Patients with existing SA approval for adefovir will be automatically granted approval for tenofovir disoproxil fumarate (300 mg tablets, Viread® and generics).

  • Patients with existing Special Authority approval for adefovir will have 6 months to meet with their prescriber and discuss transition to an alternative treatment. Their coverage of adefovir will end on May 29, 2019.

For more information, refer to the PharmaCare Coverage of Chronic Hepatitis B Treatments information sheet (PDF)

Generic Name



10 mg
Form tablet

Special Authority Criteria

Approval Period

Diagnosis of chronic hepatitis B


  1. Lamivudine resistance (previous use of lamivudine for minimum 3 months)


  1. Compliance with medications


  1. Lab work required as indicated on the chronic hepatitis B form.


Practitioner Exemptions

  • None